Yahoo! Finance: BMRN News

CFO Interview - BioPharm Asia, Inc., Michael Guo (Wall Street Transcript)

Wed, 9 Dec 2009 16:07:00 Etc/GMT

67 WALL STREET, New York - December 9, 2009 - The Wall Street Transcript has just published its China & Japan Report offering a timely review of the sector to serious investors and industry executives. This 115 page feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

Premarket roundup: Men's Wearhouse, Cisco (AP)

Wed, 9 Dec 2009 14:34:16 Etc/GMT

Among the premarket stories for Wednesday, Dec. 9, from AP Financial News: -- Shares of Men's Wearhouse Inc.'s dropped in premarket trading after issuing a fourth-quarter forecast that disappointed investors.

Ahead of the Bell: BioMarin Pharma upgraded (AP)

Wed, 9 Dec 2009 14:27:26 Etc/GMT

A Collins Stewart analyst said Wednesday she expects strong gains for shares of BioMarin Pharmaceutical Inc. after the company reports clinical data for a drug intended to treat a rare enzyme disease, and upgraded the stock to "Buy."

Biomarin Pharm upgraded by Collins Stewart (Briefing.com)

Wed, 9 Dec 2009 12:45:03 Etc/GMT

Orphan Drug Status for BioMarin Drug (Zacks.com)

Wed, 2 Dec 2009 16:16:38 Etc/GMT

BioMarin receives FDA orphan drug status for 3,4-DAP.

Pfizer Takes In an Orphan on the Cheap (at Motley Fool)

Tue, 1 Dec 2009 20:13:31 Etc/GMT

BioMed Updates: Merck KGaA, BioMarin, Cytori and Theravance (at Seeking Alpha)

Mon, 30 Nov 2009 19:10:32 Etc/GMT

UPDATE - BioMarin autoimmune disease drug gets orphan status (at Reuters)

Mon, 30 Nov 2009 14:58:16 Etc/GMT

BioMarin treatment gets special FDA status (AP)

Mon, 30 Nov 2009 14:27:10 Etc/GMT

BioMarin Pharmaceutical Inc. said Monday the Food and Drug Administration granted orphan drug designation to a developing treatment for a rare autoimmune disorder.

FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS (PR Newswire)

Mon, 30 Nov 2009 14:00:00 Etc/GMT

BioMarin Pharmaceutical Inc. announced today that the Food and Drug Administration has granted orphan drug designation for 3,4-diaminopyridine , amifampridine phosphate, for the rare autoimmune disease Lambert Eaton Myasthenic Syndrome .

Less Toxic Monoclonal Antibodies And Increased Patent Protection For Biologics Creates Multiple Positive Investment Scenarios In Biotechnology Sector (Wall Street Transcript)

Sat, 28 Nov 2009 15:23:00 Etc/GMT

67 WALL STREET, New York - November 28, 2009 - The Wall Street Transcript has recently published its Q4 2009 Biotechnology Report offering a timely review of the sector to serious investors and industry executives. This 70 page feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

The Next Million-Dollar Penny Stock (at Motley Fool)

Fri, 27 Nov 2009 16:24:33 Etc/GMT

BioMarin to Present at the NASDAQ OMX 23rd Investor Program (PR Newswire)

Tue, 24 Nov 2009 21:00:00 Etc/GMT

BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the NASDAQ OMX 23rd Investor Program in London on Tuesday, December 1, 2009 at 9:00 a.m.

Particles Detected in Vials from Genzyme's Plant Not Expected to Impact Aldurazyme or Naglazyme (PR Newswire)

Fri, 13 Nov 2009 16:58:00 Etc/GMT

BioMarin Pharmaceutical Inc. announced today that Genzyme notified the company that, in rare circumstances, it has detected foreign particles in some products filled at the Allston Landing facility.

Healthcare Bill Will Be Law By New Year Says Morningstar Strategist (Wall Street Transcript)

Mon, 9 Nov 2009 18:53:00 Etc/GMT

67 WALL STREET, New York - November 9, 2009 - The Wall Street Transcript has just published its Pharmaceuticals Report offering a timely review of the sector to serious investors and industry executives. This 76 page feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

United States Patent Office Issues Patent Covering the Approved Administration of Kuvan With Food (PR Newswire)

Thu, 5 Nov 2009 21:00:00 Etc/GMT

BioMarin Pharmaceutical Inc. announced today that the United States Patent and Trademark Office has issued a patent covering the approved administration of Kuvan® with food for the treatment of phenylketonuria .

BioMarin to Present at the Credit Suisse Healthcare Conference (PR Newswire)

Wed, 4 Nov 2009 14:00:00 Etc/GMT

BIOMARIN PHARMACEUTICAL INC Financials (EDGAR Online Financials)

Tue, 3 Nov 2009 14:04:45 Etc/GMT

Finally Convinced? Benlysta Works! (at Motley Fool)

Mon, 2 Nov 2009 18:59:56 Etc/GMT

Earnings? Yawn. Trial Data? Moving! (at Motley Fool)

Fri, 30 Oct 2009 19:37:20 Etc/GMT